Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing

Zu, Ming; Hao, Xinyu; Ning, Jing; Zhou, Xin; Gong, Yueqing; Lang, Yanfei; Xu, Wei; Zhang, Jing; Ding, Shigang

doi:10.1016/j.biopha.2023.114751

Cited by 6 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, an initial assessment of the sensitivity of tumor cells to chemotherapeutic agents used in the induction therapy of leukemia and other parameters reflecting the multidrug resistance phenotype, such as drug efflux transporters, may be useful in predicting the patient's response to antitumor therapy. Previously, in our studies related to acute leukemias [21,22], as well as in the works related to a wide range of neoplastic diseases of various histological origins (gastric cancer [33], renal cancer [34], colorectal cancer [35], osteosarcoma [36]), correlations of the therapy response and the clinical outcome of tumor patients with the drug sensitivity of their tumor cells were demonstrated. As for hematological disorders and particularly AML, many works and reviews show the clinical and prognostic relevance of drug transporter proteins [37][38][39][40][41].…”

Section: Discussionmentioning

confidence: 99%

Effective Prognostic Model for Therapy Response Prediction in Acute Myeloid Leukemia Patients

Kolesnikova¹,

Sen’kova

Поспелова

et al. 2023

JPM

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a hematopoietic disorder characterized by the malignant transformation of bone marrow-derived myeloid progenitor cells with extremely short survival. To select the optimal treatment options and predict the response to therapy, the stratification of AML patients into risk groups based on genetic factors along with clinical characteristics is carried out. Despite this thorough approach, the therapy response and disease outcome for a particular patient with AML depends on several patient- and tumor-associated factors. Among these, tumor cell resistance to chemotherapeutic agents represents one of the main obstacles for improving survival outcomes in AML patients. In our study, a new prognostic scale for the risk stratification of AML patients based on the detection of the sensitivity or resistance of tumor cells to chemotherapeutic drugs in vitro as well as MDR1 mRNA/P-glycoprotein expression, tumor origin (primary or secondary), cytogenetic abnormalities, and aberrant immunophenotype was developed. This study included 53 patients diagnosed with AML. Patients who received intensive or non-intensive induction therapy were analyzed separately. Using correlation, ROC, and Cox regression analyses, we show that the risk stratification of AML patients in accordance with the developed prognostic scale correlates well with the response to therapy and represents an independent predictive factor for the overall survival of patients with newly diagnosed AML.

show abstract

Section: Discussionmentioning

confidence: 99%

Effective Prognostic Model for Therapy Response Prediction in Acute Myeloid Leukemia Patients

Kolesnikova¹,

Sen’kova

Поспелова

et al. 2023

JPM

View full text Add to dashboard Cite

show abstract

“…Wanlu Song 1 Qingyu Meng 2 Chuanqing Qu 1 Shaohua Guo 2 Yalong Wang 3 Ronghui Tan 3 Baoqing Jia 2 Ye-Guang Chen 1,3,4…”

Section: Ting Wangmentioning

confidence: 99%

“…1 GC-derived organoids are a good model for drug tests as they preserve primary tumour features. [2][3][4][5] However, the correlation between patients' long-term clinical prognosis and drug sensitivity is unclear. The distinction between GTOs and gastric normal organoids (GNOs) is vague.…”

mentioning

confidence: 99%

Tumorigenicity and prediction of clinical prognosis of patient‐derived gastric cancer organoids

Wang,

Song,

Meng

et al. 2024

Clinical & Translational Med

View full text Add to dashboard Cite

Dear Editor,In this study, we established a biobank of gastric tumour organoids (GTOs), which retained primary tumour characteristics. The response of GTOs to drugs was correlated with individual patient's long-term postoperative prognosis, suggesting that GTOs are a good model for drug prediction for gastric cancer (GC) treatment.Varying response to chemotherapy restricts GC treatment efficacy and clinical prognosis. 1 GC-derived organoids are a good model for drug tests as they preserve primary tumour features. [2][3][4][5] However, the correlation between patients' long-term clinical prognosis and drug sensitivity is unclear. The distinction between GTOs and gastric normal organoids (GNOs) is vague. To address these questions, we established GTOs and corresponding GNOs from 17 GC patients: seven intestinal-type, eight diffuse-type and two mixed-type (Table S1). 6 Two types of GTO morphology were observed: one displaying a glandular, round pattern with an obvious lumen, similar to intestinal-type tumours; the other exhibiting a solid morphology with the nucleus shifting to one side and resembling diffuse-type tumours (Figure 1A,B). GTOs derived from mixed-type GC tissues displayed both types of morphology (Figure 1C). All GNOs derived from normal tissues displayed glandular structures, mimicking normal gastric glands (Figure 1D).To assess GTOs' tumour features, gastric tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cytokeratin 7 (CK7) were examined. CEA and CA19-9 expression were detected in GTO2, GTO3, GTO9, GTO13, GTO2-15, GTO10-11 and GTO10-21 and their corresponding GTs, but not in GNOs and normal tissues (Figure 1E-G and S1A-C). CEA and CA19-9 expression were found in 13 GTOs and their corresponding GTs (11/13 and 12/13, respectively) (Table S2). Therefore, GTOs preserved tumour marker expression of tumours, even in long-term cultures.

show abstract

“…However, stem cells can improve the formation of organoid structures when co-cultured with Paneth cells. 39 More recently, organoids have gradually improved and become widely utilized in tumor research, especially in digestive system cancers, including CRC, 40 , 41 GC, 42 , 43 PC, 19 liver cancer, 44 gastroesophageal cancer, 45 – 47 GEP-NENs, 20 pancreatic ductal adenocarcinoma (PDAC), 48 and EC 49 ( Figure 1 ).…”

Section: Overview and Characteristics Of Digestive Tract Tumor Organoidsmentioning

confidence: 99%

Revolutionizing digestive system tumor organoids research: Exploring the potential of tumor organoids

Xiu,

Yang,

Xie

et al. 2024

J Tissue Eng

View full text Add to dashboard Cite

Digestive system tumors are the leading cause of cancer-related deaths worldwide. Despite ongoing research, our understanding of their mechanisms and treatment remain inadequate. One promising tool for clinical applications is the use of gastrointestinal tract tumor organoids, which serve as an important in vitro model. Tumor organoids exhibit a genotype similar to the patient’s tumor and effectively mimic various biological processes, including tissue renewal, stem cell, and ecological niche functions, and tissue response to drugs, mutations, or injury. As such, they are valuable for drug screening, developing novel drugs, assessing patient outcomes, and supporting immunotherapy. In addition, innovative materials and techniques can be used to optimize tumor organoid culture systems. Several applications of digestive system tumor organoids have been described and have shown promising results in related aspects. In this review, we discuss the current progress, limitations, and prospects of this model for digestive system tumors.

show abstract

Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing

Cited by 6 publications

References 44 publications

Effective Prognostic Model for Therapy Response Prediction in Acute Myeloid Leukemia Patients

Effective Prognostic Model for Therapy Response Prediction in Acute Myeloid Leukemia Patients

Tumorigenicity and prediction of clinical prognosis of patient‐derived gastric cancer organoids

Revolutionizing digestive system tumor organoids research: Exploring the potential of tumor organoids

Contact Info

Product

Resources

About